{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:17:28Z","timestamp":1776241048477,"version":"3.50.1"},"reference-count":262,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11427-025-3061-8","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:26:31Z","timestamp":1770035191000},"page":"1177-1203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions"],"prefix":"10.1007","volume":"69","author":[{"given":"Shi","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqiong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"3061_CR1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., and Tamada, K. (2018). IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 36, 346\u2013351.","journal-title":"Nat Biotechnol"},{"key":"3061_CR2","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal, S., Aznar, M.A., Rech, A.J., Good, C.R., Kuramitsu, S., Da, T., Gohil, M., Chen, L., Hong, S.J.A., Ravikumar, P., et al. (2023). Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity 56, 2388\u20132407.e9.","journal-title":"Immunity"},{"key":"3061_CR3","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41587-022-01245-x","volume":"40","author":"P Agarwalla","year":"2022","unstructured":"Agarwalla, P., Ogunnaike, E.A., Ahn, S., Froehlich, K.A., Jansson, A., Ligler, F.S., Dotti, G., and Brudno, Y. (2022). Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells. Nat Biotechnol 40, 1250\u20131258.","journal-title":"Nat Biotechnol"},{"key":"3061_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","volume":"12","author":"G Agliardi","year":"2021","unstructured":"Agliardi, G., Liuzzi, A.R., Hotblack, A., De Feo, D., N\u00fa\u00f1ez, N., Stowe, C.L., Friebel, E., Nannini, F., Rindlisbacher, L., Roberts, T.A., et al. (2021). Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun 12, 444.","journal-title":"Nat Commun"},{"key":"3061_CR5","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","volume":"17","author":"A Ajina","year":"2018","unstructured":"Ajina, A., and Maher, J. (2018). Strategies to address chimeric antigen receptor tonic signaling. Mol Cancer Ther 17, 1795\u20131815.","journal-title":"Mol Cancer Ther"},{"key":"3061_CR6","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.ymthe.2021.08.003","volume":"29","author":"B Akbari","year":"2021","unstructured":"Akbari, B., Ghahri-Saremi, N., Soltantoyeh, T., Hadjati, J., Ghassemi, S., and Mirzaei, H.R. (2021). Epigenetic strategies to boost CAR T cell therapy. Mol Ther 29, 2640\u20132659.","journal-title":"Mol Ther"},{"key":"3061_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s12967-021-03146-0","volume":"19","author":"K Alishah","year":"2021","unstructured":"Alishah, K., Birtel, M., Masoumi, E., Jafarzadeh, L., Mirzaee, H.R., Hadjati, J., Voss, R. H., Diken, M., and Asad, S. (2021). CRISPR\/Cas9-mediated TGF\u03b2RII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. J Transl Med 19, 482.","journal-title":"J Transl Med"},{"key":"3061_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","volume":"74","author":"D Alizadeh","year":"2014","unstructured":"Alizadeh, D., Trad, M., Hanke, N.T., Larmonier, C.B., Janikashvili, N., Bonnotte, B., Katsanis, E., and Larmonier, N. (2014). Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res 74, 104\u2013118.","journal-title":"Cancer Res"},{"key":"3061_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh, D., Wong, R.A., Yang, X., Wang, D., Pecoraro, J.R., Kuo, C.F., Aguilar, B., Qi, Y., Ann, D.K., Starr, R., et al. (2019). IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res 7, 759\u2013772.","journal-title":"Cancer Immunol Res"},{"key":"3061_CR10","doi-asserted-by":"publisher","first-page":"a1624","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen, G.M., Frankel, N.W., Reddy, N.R., Bhargava, H.K., Yoshida, M.A., Stark, S.R., Purl, M., Lee, J., Yee, J.L., Yu, W., et al. (2022). Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science 378, a1624.","journal-title":"Science"},{"key":"3061_CR11","doi-asserted-by":"publisher","first-page":"g7565","DOI":"10.1126\/scitranslmed.abg7565","volume":"13","author":"PJ Aspuria","year":"2021","unstructured":"Aspuria, P.J., Vivona, S., Bauer, M., Semana, M., Ratti, N., McCauley, S., Riener, R., de Waal Malefyt, R., Rokkam, D., Emmerich, J., et al. (2021). An orthogonal IL-2 and IL-2R\u03b2 system drives persistence and activation of CAR T cells and clearance of bulky lymphoma. Sci Transl Med 13, g7565.","journal-title":"Sci Transl Med"},{"key":"3061_CR12","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/s41590-020-0786-2","volume":"21","author":"MA Ataide","year":"2020","unstructured":"Ataide, M.A., Komander, K., Kn\u00f6pper, K., Peters, A.E., Wu, H., Eickhoff, S., Gogishvili, T., Weber, J., Grafen, A., Kallies, A., et al. (2020). BATF3 programs CD8+ T cell memory. Nat Immunol 21, 1397\u20131407.","journal-title":"Nat Immunol"},{"key":"3061_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R., and Engleman, E.G. (2021). Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol Mech Dis 16, 223\u2013249.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"3061_CR14","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1182\/blood-2006-07-037754","volume":"109","author":"S Bandyopadhyay","year":"2007","unstructured":"Bandyopadhyay, S., Dur\u00e9, M., Paroder, M., Soto-Nieves, N., Puga, I., and Maci\u00e1n, F. (2007). Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells. Blood 109, 2878\u20132886.","journal-title":"Blood"},{"key":"3061_CR15","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.3390\/cancers13143534","volume":"13","author":"AM Battram","year":"2021","unstructured":"Battram, A.M., Bachiller, M., Lopez, V., Fern\u00e1ndez de Larrea, C., Urbano-Ispizua, A., and Mart\u00edn-Antonio, B. (2021). IL-15 enhances the persistence and function of BCMA-targeting CAR-T cells compared to IL-2 or IL-15\/IL-7 by limiting CAR-T cell dysfunction and differentiation. Cancers 13, 3534.","journal-title":"Cancers"},{"key":"3061_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1182\/bloodadvances.2024013209","volume":"9","author":"AM Battram","year":"2025","unstructured":"Battram, A.M., Ma\u00f1\u00e9-Pujol, J., Moreno, D.F., Oliver-Cald\u00e9s, A., Carpio, J., Cardus, O., Rodr\u00edguez-Lobato, L.G., Urbano-Ispizua, \u00c1., and Fern\u00e1ndez de Larrea, C. (2025). Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells. Blood Adv 9, 627\u2013641.","journal-title":"Blood Adv"},{"key":"3061_CR17","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1096\/fj.03-1001fje","volume":"18","author":"DE Bauer","year":"2004","unstructured":"Bauer, D.E., Harris, M.H., Plas, D.R., Lum, J.J., Hammerman, P.S., Rathmell, J.C., Riley, J.L., and Thompson, C.B. (2004). Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. FASEB J 18, 1303\u20131305.","journal-title":"FASEB J"},{"key":"3061_CR18","doi-asserted-by":"publisher","first-page":"e005956","DOI":"10.1136\/jitc-2022-005956","volume":"10","author":"K Baur","year":"2022","unstructured":"Baur, K., Heim, D., Beerlage, A., Poerings, A.S., Kopp, B., Medinger, M., Dirks, J.C., Passweg, J.R., and Holbro, A. (2022). Dasatinib for treatment of CAR T-cell therapy-related complications. J Immunother Cancer 10, e005956.","journal-title":"J Immunother Cancer"},{"key":"3061_CR19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1089\/hum.2023.128","volume":"34","author":"C Bonini","year":"2023","unstructured":"Bonini, C., Chapuis, A.G., Hudecek, M., Guedan, S., Magnani, C., and Qasim, W. (2023). Genome editing in engineered T cells for cancer immunotherapy. Hum Gene Ther 34, 853\u2013869.","journal-title":"Hum Gene Ther"},{"key":"3061_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1158\/2326-6066.CIR-20-0253","volume":"9","author":"JC Boucher","year":"2021","unstructured":"Boucher, J.C., Li, G., Kotani, H., Cabral, M.L., Morrissey, D., Lee, S.B., Spitler, K., Beatty, N.J., Cervantes, E.V., Shrestha, B., et al. (2021). CD28 costimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function. Cancer Immunol Res 9, 62\u201374.","journal-title":"Cancer Immunol Res"},{"key":"3061_CR21","doi-asserted-by":"publisher","first-page":"100751","DOI":"10.1016\/j.omto.2023.100751","volume":"31","author":"JC Boucher","year":"2023","unstructured":"Boucher, J.C., Shrestha, B., Vishwasrao, P., Leick, M., Cervantes, E.V., Ghafoor, T., Reid, K., Spitler, K., Yu, B., Betts, B.C., et al. (2023). Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Mol Ther Oncolytics 31, 100751.","journal-title":"Mol Ther Oncolytics"},{"key":"3061_CR22","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/bjh.19348","volume":"204","author":"H Brillembourg","year":"2024","unstructured":"Brillembourg, H., Mart\u00ednez-Cibri\u00e1n, N., Bachiller, M., Alserawan, L., Ortiz-Maldonado, V., Guedan, S., and Delgado, J. (2024). The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies. Br J Haematol 204, 1649\u20131659.","journal-title":"Br J Haematol"},{"key":"3061_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","volume":"609","author":"J Carnevale","year":"2022","unstructured":"Carnevale, J., Shifrut, E., Kale, N., Nyberg, W.A., Blaeschke, F., Chen, Y.Y., Li, Z., Bapat, S.P., Diolaiti, M.E., O\u2019Leary, P., et al. (2022). RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 609, 174\u2013182.","journal-title":"Nature"},{"key":"3061_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41590-023-01708-6","volume":"25","author":"M Casucci","year":"2024","unstructured":"Casucci, M., Bonini, C., and Ruggiero, E. (2024). Epigenetic checkpoints regulate the fate and function of CAR-T cells. Nat Immunol 25, 4\u20136.","journal-title":"Nat Immunol"},{"key":"3061_CR25","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1182\/blood-2019-122752","volume":"134","author":"EV Cervantes","year":"2019","unstructured":"Cervantes, E.V., Boucher, J.C., Lee, S.B., Spitler, K., Reid, K., and Davila, M.L. (2019). MDSC suppression of CAR T cells can be reduced by targeted signaling disruption. Blood 134, 4438.","journal-title":"Blood"},{"key":"3061_CR26","first-page":"3996","volume":"95","author":"RE Champlin","year":"2000","unstructured":"Champlin, R.E., Passweg, J.R., Zhang, M.J., Rowlings, P.A., Pelz, C.J., Atkinson, K.A., Barrett, A.J., Cahn, J.Y., Drobyski, W.R., Gale, R.P., et al. (2000). T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95, 3996\u20134003.","journal-title":"Blood"},{"key":"3061_CR27","first-page":"379","volume":"42","author":"Y Chang","year":"2024","unstructured":"Chang, Y., Chang, M., Bao, X., and Dong, C. (2024). Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment. Bioact Mater 42, 379\u2013403.","journal-title":"Bioact Mater"},{"key":"3061_CR28","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen, J., L\u00f3pez-Moyado, I.F., Seo, H., Lio, C.W.J., Hempleman, L.J., Sekiya, T., Yoshimura, A., Scott-Browne, J.P., and Rao, A. (2019a). NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567, 530\u2013534.","journal-title":"Nature"},{"key":"3061_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","volume":"33","author":"J Chen","year":"2023","unstructured":"Chen, J., Qiu, S., Li, W., Wang, K., Zhang, Y., Yang, H., Liu, B., Li, G., Li, L., Chen, M., et al. (2023a). Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. Cell Res 33, 341\u2013354.","journal-title":"Cell Res"},{"key":"3061_CR30","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","volume":"25","author":"Y Chen","year":"2019","unstructured":"Chen, Y., Sun, C., Landoni, E., Metelitsa, L., Dotti, G., and Savoldo, B. (2019b). Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15. Clin Cancer Res 25, 2915\u20132924.","journal-title":"Clin Cancer Res"},{"key":"3061_CR31","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s11427-022-2173-9","volume":"66","author":"Z Chen","year":"2023","unstructured":"Chen, Z., Liu, Y., Chen, N., Xing, H., Tian, Z., Tang, K., Rao, Q., Xu, Y., Wang, Y., Wang, M., et al. (2023b). Loop CD20\/CD19 CAR-T cells eradicate B-cell malignancies efficiently. Sci China Life Sci 66, 754\u2013770.","journal-title":"Sci China Life Sci"},{"key":"3061_CR32","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky, L., Morello, A., Villena-Vargas, J., Feng, Y., Dimitrov, D.S., Jones, D.R., Sadelain, M., and Adusumilli, P.S. (2016). Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 126, 3130\u20133144.","journal-title":"J Clin Invest"},{"key":"3061_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nbt.4047","volume":"36","author":"AS Cheung","year":"2018","unstructured":"Cheung, A.S., Zhang, D.K.Y., Koshy, S.T., and Mooney, D.J. (2018). Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells. Nat Biotechnol 36, 160\u2013169.","journal-title":"Nat Biotechnol"},{"key":"3061_CR34","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi, B.D., Yu, X., Castano, A.P., Bouffard, A.A., Schmidts, A., Larson, R.C., Bailey, S. R., Boroughs, A.C., Frigault, M.J., Leick, M.B., et al. (2019a). CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol 37, 1049\u20131058.","journal-title":"Nat Biotechnol"},{"key":"3061_CR35","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","volume":"7","author":"BD Choi","year":"2019","unstructured":"Choi, B.D., Yu, X., Castano, A.P., Darr, H., Henderson, D.B., Bouffard, A.A., Larson, R. C., Scarf\u00f2, I., Bailey, S.R., Gerhard, G.M., et al. (2019b). CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer 7, 304.","journal-title":"J Immunother Cancer"},{"key":"3061_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13238-020-00796-6","volume":"12","author":"B Cong","year":"2021","unstructured":"Cong, B., Zhang, Q., and Cao, X. (2021). The function and regulation of TET2 in innate immunity and inflammation. Protein Cell 12, 165\u2013173.","journal-title":"Protein Cell"},{"key":"3061_CR37","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41375-022-01572-7","volume":"36","author":"MJ Cox","year":"2022","unstructured":"Cox, M.J., Manriquez Roman, C., Tapper, E.E., Siegler, E.L., Chappell, D., Durrant, C., Ahmed, O., Sinha, S., Mwangi, R., Scott, N.S., et al. (2022). GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia 36, 1635\u20131645.","journal-title":"Leukemia"},{"key":"3061_CR38","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","volume":"33","author":"JA Craddock","year":"2010","unstructured":"Craddock, J.A., Lu, A., Bear, A., Pule, M., Brenner, M.K., Rooney, C.M., and Foster, A. E. (2010). Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 33, 780\u2013788.","journal-title":"J Immunother"},{"key":"3061_CR39","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.immuni.2011.09.017","volume":"35","author":"W Cui","year":"2011","unstructured":"Cui, W., Liu, Y., Weinstein, J.S., Craft, J., and Kaech, S.M. (2011). An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity 35, 792\u2013805.","journal-title":"Immunity"},{"key":"3061_CR40","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/mt.2015.4","volume":"23","author":"KJ Curran","year":"2015","unstructured":"Curran, K.J., Seinstra, B.A., Nikhamin, Y., Yeh, R., Usachenko, Y., van Leeuwen, D.G., Purdon, T., Pegram, H.J., and Brentjens, R.J. (2015). Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther 23, 769\u2013778.","journal-title":"Mol Ther"},{"key":"3061_CR41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.tips.2024.10.016","volume":"45","author":"C D\u2019Avanzo","year":"2024","unstructured":"D\u2019Avanzo, C., Blaeschke, F., Lysandrou, M., Ingelfinger, F., and Zeiser, R. (2024). Advances in cell therapy: progress and challenges in hematological and solid tumors. Trends Pharmacol Sci 45, 1119\u20131134.","journal-title":"Trends Pharmacol Sci"},{"key":"3061_CR42","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/mt.2012.267","volume":"21","author":"DC Deniger","year":"2013","unstructured":"Deniger, D.C., Switzer, K., Mi, T., Maiti, S., Hurton, L., Singh, H., Huls, H., Olivares, S., Lee, D.A., Champlin, R.E., et al. (2013). Bispecific T-cells expressing polyclonal repertoire of endogenous \u03b3\u03b4 T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther 21, 638\u2013647.","journal-title":"Mol Ther"},{"key":"3061_CR43","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","volume":"113","author":"A Di Stasi","year":"2009","unstructured":"Di Stasi, A., De Angelis, B., Rooney, C.M., Zhang, L., Mahendravada, A., Foster, A.E., Heslop, H.E., Brenner, M.K., Dotti, G., and Savoldo, B. (2009). T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113, 6392\u20136402.","journal-title":"Blood"},{"key":"3061_CR44","doi-asserted-by":"publisher","first-page":"eaba5962","DOI":"10.1126\/sciimmunol.aba5962","volume":"5","author":"ZC Ding","year":"2020","unstructured":"Ding, Z.C., Shi, H., Aboelella, N.S., Fesenkova, K., Park, E.J., Liu, Z., Pei, L., Li, J., McIndoe, R.A., Xu, H., et al. (2020). Persistent STAT5 activation reprograms the epigenetic landscape in CD4+ T cells to drive polyfunctionality and antitumor immunity. Sci Immunol 5, eaba5962.","journal-title":"Sci Immunol"},{"key":"3061_CR45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan, A.E., Mueller, K.P., Chen, A.Y., Rouin, G.T., Chen, Y., Daniel, B., Lattin, J., Markovska, M., Mozarsky, B., Arias-Umana, J., et al. (2024). FOXO1 is a master regulator of memory programming in CAR T cells. Nature 629, 211\u2013218.","journal-title":"Nature"},{"key":"3061_CR46","doi-asserted-by":"publisher","first-page":"e2094341176","DOI":"10.1073\/pnas.2200626120","volume":"120","author":"S D\u00f6tsch","year":"2023","unstructured":"D\u00f6tsch, S., Svec, M., Schober, K., Hammel, M., Wanisch, A., G\u00f6kmen, F., Jarosch, S., Warmuth, L., Barton, J., Cicin-Sain, L., et al. (2023). Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression. Proc Natl Acad Sci USA 120, e2094341176.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3061_CR47","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","volume":"35","author":"ME Dourthe","year":"2021","unstructured":"Dourthe, M.E., Rabian, F., Yakouben, K., Chevillon, F., Cabannes-Hamy, A., M\u00e9chinaud, F., Grain, A., Chaillou, D., Rahal, I., Caillat-Zucman, S., et al. (2021). Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia 35, 3383\u20133393.","journal-title":"Leukemia"},{"key":"3061_CR48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00018-021-04089-x","volume":"79","author":"Y Duan","year":"2021","unstructured":"Duan, Y., Chen, R., Huang, Y., Meng, X., Chen, J., Liao, C., Tang, Y., Zhou, C., Gao, X., and Sun, J. (2021). Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cell Mol Life Sci 79, 14.","journal-title":"Cell Mol Life Sci"},{"key":"3061_CR49","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S.J.C., Hamieh, M., Cunanan, K.M., Odak, A., G\u00f6nen, M., and Sadelain, M. (2017). Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117.","journal-title":"Nature"},{"key":"3061_CR50","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","volume":"634","author":"B Feng","year":"2024","unstructured":"Feng, B., Bai, Z., Zhou, X., Zhao, Y., Xie, Y.Q., Huang, X., Liu, Y., Enbar, T., Li, R., Wang, Y., et al. (2024). The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8+ T cells against cancer. Nature 634, 712\u2013720.","journal-title":"Nature"},{"key":"3061_CR51","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"C Fern\u00e1ndez de Larrea","year":"2020","unstructured":"Fern\u00e1ndez de Larrea, C., Staehr, M., Lopez, A.V., Ng, K.Y., Chen, Y., Godfrey, W.D., Purdon, T.J., Ponomarev, V., Wendel, H.G., Brentjens, R.J., et al. (2020). Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov 1, 146\u2013154.","journal-title":"Blood Cancer Discov"},{"key":"3061_CR52","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J., Sun, J., Eyquem, J., Ho, Y.J., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., and Sadelain, M. (2019). Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med 25, 82\u201388.","journal-title":"Nat Med"},{"key":"3061_CR53","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.ymthe.2017.03.002","volume":"25","author":"J Fisher","year":"2017","unstructured":"Fisher, J., Abramowski, P., Wisidagamage Don, N.D., Flutter, B., Capsomidis, A., Cheung, G.W.K., Gustafsson, K., and Anderson, J. (2017). Avoidance of on-target off-tumor activation using a co-stimulation-only chimeric antigen receptor. Mol Ther 25, 1234\u20131247.","journal-title":"Mol Ther"},{"key":"3061_CR54","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00262-012-1237-1","volume":"61","author":"TS Fisher","year":"2012","unstructured":"Fisher, T.S., Kamperschroer, C., Oliphant, T., Love, V.A., Lira, P.D., Doyonnas, R., Bergqvist, S., Baxi, S.M., Rohner, A., Shen, A.C., et al. (2012). Targeting of 4\u20131BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother 61, 1721\u20131733.","journal-title":"Cancer Immunol Immunother"},{"key":"3061_CR55","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nm.4275","volume":"23","author":"P Fisicaro","year":"2017","unstructured":"Fisicaro, P., Barili, V., Montanini, B., Acerbi, G., Ferracin, M., Guerrieri, F., Salerno, D., Boni, C., Massari, M., Cavallo, M.C., et al. (2017). Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat Med 23, 327\u2013336.","journal-title":"Nat Med"},{"key":"3061_CR56","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J.A., Nobles, C.L., Sammons, M.A., Lundh, S., Carty, S.A., Reich, T.J., Cogdill, A.P., Morrissette, J.J.D., DeNizio, J.E., Reddy, S., et al. (2018). Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312.","journal-title":"Nature"},{"key":"3061_CR57","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","volume":"2","author":"F Franco","year":"2020","unstructured":"Franco, F., Jaccard, A., Romero, P., Yu, Y.R., and Ho, P.C. (2020). Metabolic and epigenetic regulation of T-cell exhaustion. Nat Metab 2, 1001\u20131012.","journal-title":"Nat Metab"},{"key":"3061_CR58","doi-asserted-by":"publisher","first-page":"eabn5647","DOI":"10.1126\/science.abn5647","volume":"378","author":"KA Freitas","year":"2022","unstructured":"Freitas, K.A., Belk, J.A., Sotillo, E., Quinn, P.J., Ramello, M.C., Malipatlolla, M., Daniel, B., Sandor, K., Klysz, D., Bjelajac, J., et al. (2022). Enhanced T cell effector activity by targeting the Mediator kinase module. Science 378, eabn5647.","journal-title":"Science"},{"key":"3061_CR59","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1182\/blood.2019004500","volume":"136","author":"L Fultang","year":"2020","unstructured":"Fultang, L., Booth, S., Yogev, O., Martins da Costa, B., Tubb, V., Panetti, S., Stavrou, V., Scarpa, U., Jankevics, A., Lloyd, G., et al. (2020). Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood 136, 1155\u20131160.","journal-title":"Blood"},{"key":"3061_CR60","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi, A.K., Kang, J., Havens, C.G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M.F., Thakurta, A., et al. (2014). Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN. Br J Haematol 164, 811\u2013821.","journal-title":"Br J Haematol"},{"key":"3061_CR61","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s11427-023-2499-2","volume":"67","author":"K Ganesan","year":"2024","unstructured":"Ganesan, K., Xu, C., Wu, J., Du, B., Liu, Q., Sui, Y., Song, C., Zhang, J., Tang, H., and Chen, J. (2024). Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K\/Akt\/mTOR pathway. Sci China Life Sci 67, 1849\u20131866.","journal-title":"Sci China Life Sci"},{"key":"3061_CR62","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-019-0511-6","volume":"7","author":"Q Gao","year":"2019","unstructured":"Gao, Q., Wang, S., Chen, X., Cheng, S., Zhang, Z., Li, F., Huang, L., Yang, Y., Zhou, B., Yue, D., et al. (2019). Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer 7, 42.","journal-title":"J Immunother Cancer"},{"key":"3061_CR63","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/mt.2016.63","volume":"24","author":"T Gargett","year":"2016","unstructured":"Gargett, T., Yu, W., Dotti, G., Yvon, E.S., Christo, S.N., Hayball, J.D., Lewis, I.D., Brenner, M.K., and Brown, M.P. (2016). GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther 24, 1135\u20131149.","journal-title":"Mol Ther"},{"key":"3061_CR64","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","volume":"6","author":"S Ghassemi","year":"2022","unstructured":"Ghassemi, S., Durgin, J.S., Nunez-Cruz, S., Patel, J., Leferovich, J., Pinzone, M., Shen, F., Cummins, K.D., Plesa, G., Cantu, V.A., et al. (2022). Rapid manufacturing of non-activated potent CAR T cells. Nat Biomed Eng 6, 118\u2013128.","journal-title":"Nat Biomed Eng"},{"key":"3061_CR65","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi, S., Nunez-Cruz, S., O\u2019Connor, R.S., Fraietta, J.A., Patel, P.R., Scholler, J., Barrett, D.M., Lundh, S.M., Davis, M.M., Bedoya, F., et al. (2018). Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol Res 6, 1100\u20131109.","journal-title":"Cancer Immunol Res"},{"key":"3061_CR66","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","volume":"12","author":"L Giuffrida","year":"2021","unstructured":"Giuffrida, L., Sek, K., Henderson, M.A., Lai, J., Chen, A.X.Y., Meyran, D., Todd, K.L., Petley, E.V., Mardiana, S., M\u00f8lck, C., et al. (2021). CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat Commun 12, 3236.","journal-title":"Nat Commun"},{"key":"3061_CR67","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","volume":"184","author":"CR Good","year":"2021","unstructured":"Good, C.R., Aznar, M.A., Kuramitsu, S., Samareh, P., Agarwal, S., Donahue, G., Ishiyama, K., Wellhausen, N., Rennels, A.K., Ma, Y., et al. (2021). An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184, 6081\u20136100.e26.","journal-title":"Cell"},{"key":"3061_CR68","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.3860","volume":"35","author":"GG Gornalusse","year":"2017","unstructured":"Gornalusse, G.G., Hirata, R.K., Funk, S.E., Riolobos, L., Lopes, V.S., Manske, G., Prunkard, D., Colunga, A.G., Hanafi, L.A., Clegg, D.O., et al. (2017). HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol 35, 765\u2013772.","journal-title":"Nat Biotechnol"},{"key":"3061_CR69","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368, 1509\u20131518.","journal-title":"N Engl J Med"},{"key":"3061_CR70","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1631\/jzus.B2200256","volume":"23","author":"T Gu","year":"2022","unstructured":"Gu, T., Zhu, M., Huang, H., and Hu, Y. (2022). Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. J Zhejiang Univ Sci B 23, 793\u2013811.","journal-title":"J Zhejiang Univ Sci B"},{"key":"3061_CR71","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1172\/JCI133215","volume":"130","author":"S Guedan","year":"2020","unstructured":"Guedan, S., Madar, A., Casado-Medrano, V., Shaw, C., Wing, A., Liu, F., Young, R.M., June, C.H., and PoseyJr., A.D. (2020). Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. J Clin Invest 130, 3087\u20133097.","journal-title":"J Clin Invest"},{"key":"3061_CR72","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41586-022-04849-0","volume":"607","author":"A Guo","year":"2022","unstructured":"Guo, A., Huang, H., Zhu, Z., Chen, M.J., Shi, H., Yuan, S., Sharma, P., Connelly, J.P., Liedmann, S., Dhungana, Y., et al. (2022). cBAF complex components and MYC cooperate early in CD8+ T cell fate. Nature 607, 135\u2013141.","journal-title":"Nature"},{"key":"3061_CR73","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3389\/fphar.2018.01118","volume":"9","author":"X Guo","year":"2018","unstructured":"Guo, X., Jiang, H., Shi, B., Zhou, M., Zhang, H., Shi, Z., Du, G., Luo, H., Wu, X., Wang, Y., et al. (2018). Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma. Front Pharmacol 9, 1118.","journal-title":"Front Pharmacol"},{"key":"3061_CR74","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.ccell.2020.05.004","volume":"37","author":"D Gurusamy","year":"2020","unstructured":"Gurusamy, D., Henning, A.N., Yamamoto, T.N., Yu, Z., Zacharakis, N., Krishna, S., Kishton, R.J., Vodnala, S.K., Eidizadeh, A., Jia, L., et al. (2020). Multi-phenotype CRISPR-Cas9 screen identifies p38 kinase as a target for adoptive immunotherapies. Cancer Cell 37, 818\u2013833.e9.","journal-title":"Cancer Cell"},{"key":"3061_CR75","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/ni1046","volume":"5","author":"I Gyory","year":"2004","unstructured":"Gyory, I., Wu, J., Fej\u00e9r, G., Seto, E., and Wright, K.L. (2004). PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol 5, 299\u2013308.","journal-title":"Nat Immunol"},{"key":"3061_CR76","doi-asserted-by":"publisher","first-page":"e13309","DOI":"10.1111\/acel.13309","volume":"20","author":"JAG Hamilton","year":"2021","unstructured":"Hamilton, J.A.G., Lee, M.Y., Hunter, R., Ank, R.S., Story, J.Y., Talekar, G., Sisroe, T., Ballak, D.B., Fedanov, A., Porter, C.C., et al. (2021). Interleukin-37 improves T-cell-mediated immunity and chimeric antigen receptor T-cell therapy in aged backgrounds. Aging Cell 20, e13309.","journal-title":"Aging Cell"},{"key":"3061_CR77","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1016\/j.immuni.2021.11.004","volume":"54","author":"BS Hanna","year":"2021","unstructured":"Hanna, B.S., Lla\u00f3-Cid, L., Iskar, M., Roessner, P.M., Klett, L.C., Wong, J.K.L., Paul, Y., Ioannou, N., \u00d6zt\u00fcrk, S., Mack, N., et al. (2021). Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity. Immunity 54, 2825\u20132841.e10.","journal-title":"Immunity"},{"key":"3061_CR78","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","volume":"200","author":"DT Harris","year":"2018","unstructured":"Harris, D.T., Hager, M.V., Smith, S.N., Cai, Q., Stone, J.D., Kruger, P., Lever, M., Dushek, O., Schmitt, T.M., Greenberg, P.D., et al. (2018). Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains. J Immunol 200, 1088\u20131100.","journal-title":"J Immunol"},{"key":"3061_CR79","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He, X., and Xu, C. (2020). Immune checkpoint signaling and cancer immunotherapy. Cell Res 30, 660\u2013669.","journal-title":"Cell Res"},{"key":"3061_CR80","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/cac2.12575","volume":"44","author":"C Heuser-Loy","year":"2024","unstructured":"Heuser-Loy, C. (2024). Interleukin-10 gives exhausted chimeric antigen receptor (CAR) T cells a second breath. Cancer Commun 44, 787\u2013790.","journal-title":"Cancer Commun"},{"key":"3061_CR81","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/biom12091303","volume":"12","author":"MM Honikel","year":"2022","unstructured":"Honikel, M.M., and Olejniczak, S.H. (2022). Co-stimulatory receptor signaling in CAR-T cells. Biomolecules 12, 1303.","journal-title":"Biomolecules"},{"key":"3061_CR82","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu, B., Ren, J., Luo, Y., Keith, B., Young, R.M., Scholler, J., Zhao, Y., and June, C.H. (2017). Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep 20, 3025\u20133033.","journal-title":"Cell Rep"},{"key":"3061_CR83","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","volume":"68","author":"W Hu","year":"2019","unstructured":"Hu, W., Zi, Z., Jin, Y., Li, G., Shao, K., Cai, Q., Ma, X., and Wei, F. (2019). CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother 68, 365\u2013377.","journal-title":"Cancer Immunol Immunother"},{"key":"3061_CR84","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","volume":"27","author":"Y Hu","year":"2021","unstructured":"Hu, Y., Zhou, Y., Zhang, M., Ge, W., Li, Y., Yang, L., Wei, G., Han, L., Wang, H., Yu, S., et al. (2021). CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res 27, 2764\u20132772.","journal-title":"Clin Cancer Res"},{"key":"3061_CR85","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"R Huang","year":"2020","unstructured":"Huang, R., Li, X., He, Y., Zhu, W., Gao, L., Liu, Y., Gao, L., Wen, Q., Zhong, J.F., Zhang, C., et al. (2020). Recent advances in CAR-T cell engineering. J Hematol Oncol 13, 86.","journal-title":"J Hematol Oncol"},{"key":"3061_CR86","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.stem.2024.02.003","volume":"31","author":"Y Huang","year":"2024","unstructured":"Huang, Y., and Wang, H. (2024). From suppressor to enhancer: IL-10\u2019s alternative role in CAR-T cell therapies against solid tumors. Cell Stem Cell 31, 285\u2013287.","journal-title":"Cell Stem Cell"},{"key":"3061_CR87","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11684-025-1130-x","volume":"19","author":"Y Huang","year":"2025","unstructured":"Huang, Y., and Wang, H. (2025). Tonic signaling in CAR-T therapy: the lever long enough to move the planet. Front Med 19, 391\u2013408.","journal-title":"Front Med"},{"key":"3061_CR88","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton, L.V., Singh, H., Najjar, A.M., Switzer, K.C., Mi, T., Maiti, S., Olivares, S., Rabinovich, B., Huls, H., Forget, M.A., et al. (2016). Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci USA 113, E7788.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3061_CR89","doi-asserted-by":"publisher","first-page":"e136185","DOI":"10.1172\/jci.insight.136185","volume":"5","author":"Y Imura","year":"2020","unstructured":"Imura, Y., Ando, M., Kondo, T., Ito, M., and Yoshimura, A. (2020). CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD. JCI Insight 5, e136185.","journal-title":"JCI Insight"},{"key":"3061_CR90","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s41232-024-00324-7","volume":"44","author":"Y Ito","year":"2024","unstructured":"Ito, Y., Inoue, S., and Kagoya, Y. (2024). Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy. Inflamm Regener 44, 13.","journal-title":"Inflamm Regener"},{"key":"3061_CR91","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1111\/cas.15541","volume":"113","author":"Y Ito","year":"2022","unstructured":"Ito, Y., and Kagoya, Y. (2022). Epigenetic engineering for optimal chimeric antigen receptor T cell therapy. Cancer Sci 113, 3664\u20133671.","journal-title":"Cancer Sci"},{"key":"3061_CR92","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41586-023-06546-y","volume":"621","author":"A Jaccard","year":"2023","unstructured":"Jaccard, A., Wyss, T., Maldonado-P\u00e9rez, N., Rath, J.A., Bevilacqua, A., Peng, J.J., Lepez, A., Von Gunten, C., Franco, F., Kao, K.C., et al. (2023). Reductive carboxylation epigenetically instructs T cell differentiation. Nature 621, 849\u2013856.","journal-title":"Nature"},{"key":"3061_CR93","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/2159-8290.CD-21-1586","volume":"12","author":"Z Jackson","year":"2022","unstructured":"Jackson, Z., Hong, C., Schauner, R., Dropulic, B., Caimi, P.F., de Lima, M., Giraudo, M. F., Gupta, K., Reese, J.S., Hwang, T.H., et al. (2022). Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma. Cancer Discov 12, 1886\u20131903.","journal-title":"Cancer Discov"},{"key":"3061_CR94","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1158\/1078-0432.CCR-23-0916","volume":"29","author":"MD Jain","year":"2023","unstructured":"Jain, M.D., Miklos, D.B., Jacobson, C.A., Timmerman, J.M., Sun, J., Nater, J., Fang, X., Patel, A., Davis, M., Heeke, D., et al. (2023a). Axicabtagene ciloleucel in combination with the 4\u20131BB agonist utomilumab in patients with relapsed\/refractory large B-cell lymphoma: phase 1 results from ZUMA-11. Clin Cancer Res 29, 4118\u20134127.","journal-title":"Clin Cancer Res"},{"key":"3061_CR95","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-022-05692-z","volume":"615","author":"N Jain","year":"2023","unstructured":"Jain, N., Zhao, Z., Feucht, J., Koche, R., Iyer, A., Dobrin, A., Mansilla-Soto, J., Yang, J., Zhan, Y., Lopez, M., et al. (2023b). TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature 615, 315\u2013322.","journal-title":"Nature"},{"key":"3061_CR96","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1172\/JCI65899","volume":"124","author":"C Jandus","year":"2014","unstructured":"Jandus, C., Boligan, K.F., Chijioke, O., Liu, H., Dahlhaus, M., D\u00e9moulins, T., Schneider, C., Wehrli, M., Hunger, R.E., Baerlocher, G.M., et al. (2014). Interactions between Siglec-7\/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest 124, 1810\u20131820.","journal-title":"J Clin Invest"},{"key":"3061_CR97","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin, L., Tao, H., Karachi, A., Long, Y., Hou, A.Y., Na, M., Dyson, K.A., Grippin, A.J., Deleyrolle, L.P., Zhang, W., et al. (2019). CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun 10, 4016.","journal-title":"Nat Commun"},{"key":"3061_CR98","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"X Jing","year":"2019","unstructured":"Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., and Shu, Y. (2019). Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer 18, 157.","journal-title":"Mol Cancer"},{"key":"3061_CR99","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1158\/2159-8290.CD-22-1175","volume":"13","author":"IY Jung","year":"2023","unstructured":"Jung, I.Y., Bartoszek, R.L., Rech, A.J., Collins, S.M., Ooi, S.K., Williams, E.F., Hopkins, C.R., Narayan, V., Haas, N.B., Frey, N.V., et al. (2023). Type I interferon signaling via the EGR2 transcriptional regulator potentiates CAR T cell-intrinsic dysfunction. Cancer Discov 13, 1636\u20131655.","journal-title":"Cancer Discov"},{"key":"3061_CR100","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1158\/0008-5472.CAN-18-0030","volume":"78","author":"IY Jung","year":"2018","unstructured":"Jung, I.Y., Kim, Y.Y., Yu, H.S., Lee, M., Kim, S., and Lee, J. (2018). CRISPR\/Cas9-mediated knockout of DGK improves antitumor activities of human T cells. Cancer Res 78, 4692\u20134703.","journal-title":"Cancer Res"},{"key":"3061_CR101","doi-asserted-by":"publisher","first-page":"n7336","DOI":"10.1126\/scitranslmed.abn7336","volume":"14","author":"IY Jung","year":"2022","unstructured":"Jung, I.Y., Narayan, V., McDonald, S., Rech, A.J., Bartoszek, R., Hong, G., Davis, M.M., Xu, J., Boesteanu, A.C., Barber-Rotenberg, J.S., et al. (2022). BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Sci Transl Med 14, n7336.","journal-title":"Sci Transl Med"},{"key":"3061_CR102","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/ijms23010144","volume":"23","author":"S Kadomoto","year":"2021","unstructured":"Kadomoto, S., Izumi, K., and Mizokami, A. (2021). Macrophage polarity and disease control. Int J Mol Sci 23, 144.","journal-title":"Int J Mol Sci"},{"key":"3061_CR103","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya, Y., Tanaka, S., Guo, T., Anczurowski, M., Wang, C.H., Saso, K., Butler, M.O., Minden, M.D., and Hirano, N. (2018). A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med 24, 352\u2013359.","journal-title":"Nat Med"},{"key":"3061_CR104","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","volume":"607","author":"A Kalbasi","year":"2022","unstructured":"Kalbasi, A., Siurala, M., Su, L.L., Tariveranmoshabad, M., Picton, L.K., Ravikumar, P., Li, P., Lin, J.X., Escuin-Ordinas, H., Da, T., et al. (2022). Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature 607, 360\u2013365.","journal-title":"Nature"},{"key":"3061_CR105","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O.U., O\u2019Connor, R.S., Fraietta, J.A., Guo, L., McGettigan, S.E., PoseyJr., A. D., Patel, P.R., Guedan, S., Scholler, J., Keith, B., et al. (2016). Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380\u2013390.","journal-title":"Immunity"},{"key":"3061_CR106","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","volume":"42","author":"DD Klysz","year":"2024","unstructured":"Klysz, D.D., Fowler, C., Malipatlolla, M., Stuani, L., Freitas, K.A., Chen, Y., Meier, S., Daniel, B., Sandor, K., Xu, P., et al. (2024). Inosine induces stemness features in CAR-T cells and enhances potency. Cancer Cell 42, 266\u2013282.e8.","journal-title":"Cancer Cell"},{"key":"3061_CR107","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.ymthe.2023.03.020","volume":"31","author":"E Kokalaki","year":"2023","unstructured":"Kokalaki, E., Ma, B., Ferrari, M., Grothier, T., Hazelton, W., Manzoor, S., Costu, E., Taylor, J., Bulek, A., Srivastava, S., et al. (2023). Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR. Mol Ther 31, 2089\u20132104.","journal-title":"Mol Ther"},{"key":"3061_CR108","doi-asserted-by":"publisher","first-page":"e145459","DOI":"10.1172\/JCI145459","volume":"131","author":"W Kong","year":"2021","unstructured":"Kong, W., Dimitri, A., Wang, W., Jung, I.Y., Ott, C.J., Fasolino, M., Wang, Y., Kulikovskaya, I., Gupta, M., Yoder, T., et al. (2021). BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. J Clin Invest 131, e145459.","journal-title":"J Clin Invest"},{"key":"3061_CR109","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides, T. (2007). Chromatin modifications and their function. Cell 128, 693\u2013705.","journal-title":"Cell"},{"key":"3061_CR110","doi-asserted-by":"publisher","first-page":"1005582","DOI":"10.3389\/fimmu.2022.1005582","volume":"13","author":"J Kremer","year":"2022","unstructured":"Kremer, J., Henschel, P., Simon, D., Riet, T., Falk, C., Hardtke-Wolenski, M., Wedemeyer, H., Noyan, F., and Jaeckel, E. (2022). Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors. Front Immunol 13, 1005582.","journal-title":"Front Immunol"},{"key":"3061_CR111","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","volume":"182","author":"MF Krummel","year":"1995","unstructured":"Krummel, M.F., and Allison, J.P. (1995). CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182, 459\u2013465.","journal-title":"J Exp Med"},{"key":"3061_CR112","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn, N.F., Purdon, T.J., van Leeuwen, D.G., Lopez, A.V., Curran, K.J., Daniyan, A.F., and Brentjens, R.J. (2019). CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 35, 473\u2013488.e6.","journal-title":"Cancer Cell"},{"key":"3061_CR113","doi-asserted-by":"publisher","first-page":"e001688","DOI":"10.1136\/jitc-2020-001688","volume":"9","author":"J Kumar","year":"2021","unstructured":"Kumar, J., Kumar, R., Kumar Singh, A., Tsakem, E.L., Kathania, M., Riese, M.J., Theiss, A.L., Davila, M.L., and Venuprasad, K. (2021). Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function. J Immunother Cancer 9, e001688.","journal-title":"J Immunother Cancer"},{"key":"3061_CR114","doi-asserted-by":"publisher","first-page":"e009221","DOI":"10.1136\/jitc-2024-009221","volume":"12","author":"JA Lake","year":"2024","unstructured":"Lake, J.A., Woods, E., Hoffmeyer, E., Schaller, K.L., Cruz-Cruz, J., Fernandez, J., Tufa, D., Kooiman, B., Hall, S.C., Jones, D., et al. (2024). Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma. J Immunother Cancer 12, e009221.","journal-title":"J Immunother Cancer"},{"key":"3061_CR115","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ymthe.2021.10.004","volume":"30","author":"YH Lee","year":"2022","unstructured":"Lee, Y.H., Lee, H.J., Kim, H.C., Lee, Y., Nam, S.K., Hupperetz, C., Ma, J.S.Y., Wang, X., Singer, O., Kim, W.S., et al. (2022). PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Mol Ther 30, 579\u2013592.","journal-title":"Mol Ther"},{"key":"3061_CR116","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-022-04494-7","volume":"603","author":"M Legut","year":"2022","unstructured":"Legut, M., Gajic, Z., Guarino, M., Daniloski, Z., Rahman, J.A., Xue, X., Lu, C., Lu, L., Mimitou, E.P., Hao, S., et al. (2022). A genome-scale screen for synthetic drivers of T cell proliferation. Nature 603, 728\u2013735.","journal-title":"Nature"},{"key":"3061_CR117","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41421-023-00625-0","volume":"10","author":"W Lei","year":"2024","unstructured":"Lei, W., Zhao, A., Liu, H., Yang, C., Wei, C., Guo, S., Chen, Z., Guo, Q., Li, L., Zhao, M., et al. (2024). Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. Cell Discov 10, 5.","journal-title":"Cell Discov"},{"key":"3061_CR118","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","volume":"40","author":"MB Leick","year":"2022","unstructured":"Leick, M.B., Silva, H., Scarf\u00f2, I., Larson, R., Choi, B.D., Bouffard, A.A., Gallagher, K., Schmidts, A., Bailey, S.R., Kann, M.C., et al. (2022). Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell 40, 494\u2013508.e5.","journal-title":"Cancer Cell"},{"key":"3061_CR119","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00262-018-2186-0","volume":"67","author":"RD Leone","year":"2018","unstructured":"Leone, R.D., Sun, I.M., Oh, M.H., Sun, I.H., Wen, J., Englert, J., and Powell, J.D. (2018). Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Cancer Immunol Immunother 67, 1271\u20131284.","journal-title":"Cancer Immunol Immunother"},{"key":"3061_CR120","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.omto.2021.07.003","volume":"22","author":"G Li","year":"2021","unstructured":"Li, G., Guo, J., Zheng, Y., Ding, W., Han, Z., Qin, L., Mo, W., and Luo, M. (2021a). CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells. Mol Ther Oncolytics 22, 507\u2013517.","journal-title":"Mol Ther Oncolytics"},{"key":"3061_CR121","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1038\/s41467-022-29647-0","volume":"13","author":"H Li","year":"2022","unstructured":"Li, H., Harrison, E.B., Li, H., Hirabayashi, K., Chen, J., Li, Q.X., Gunn, J., Weiss, J., Savoldo, B., Parker, J.S., et al. (2022a). Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration. Nat Commun 13, 2154.","journal-title":"Nat Commun"},{"key":"3061_CR122","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., and Wang, Y. (2021b). Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Sig Transduct Target Ther 6, 362.","journal-title":"Sig Transduct Target Ther"},{"key":"3061_CR123","doi-asserted-by":"publisher","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","volume":"23","author":"S Li","year":"2017","unstructured":"Li, S., Siriwon, N., Zhang, X., Yang, S., Jin, T., He, F., Kim, Y.J., Mac, J., Lu, Z., Wang, S., et al. (2017). Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors. Clin Cancer Res 23, 6982\u20136992.","journal-title":"Clin Cancer Res"},{"key":"3061_CR124","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.immuni.2020.07.011","volume":"53","author":"W Li","year":"2020","unstructured":"Li, W., Qiu, S., Chen, J., Jiang, S., Chen, W., Jiang, J., Wang, F., Si, W., Shu, Y., Wei, P., et al. (2020). Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy. Immunity 53, 456\u2013470.e6.","journal-title":"Immunity"},{"key":"3061_CR125","doi-asserted-by":"publisher","first-page":"1052717","DOI":"10.3389\/fimmu.2022.1052717","volume":"13","author":"W Li","year":"2022","unstructured":"Li, W., Zhu, X., Xu, Y., Chen, J., Zhang, H., Yang, Z., Qi, Y., Hong, J., Li, Y., Wang, G., et al. (2022b). Simultaneous editing of TCR, HLA-I\/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection. Front Immunol 13, 1052717.","journal-title":"Front Immunol"},{"key":"3061_CR126","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41375-020-0874-1","volume":"35","author":"X Li","year":"2021","unstructured":"Li, X., Daniyan, A.F., Lopez, A.V., Purdon, T.J., and Brentjens, R.J. (2021c). Cytokine IL-36\u03b3 improves CAR T-cell functionality and induces endogenous antitumor response. Leukemia 35, 506\u2013521.","journal-title":"Leukemia"},{"key":"3061_CR127","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41591-018-0302-5","volume":"25","author":"H Liu","year":"2019","unstructured":"Liu, H., Golji, J., Brodeur, L.K., Chung, F.S., Chen, J.T., deBeaumont, R.S., Bullock, C. P., Jones, M.D., Kerr, G., Li, L., et al. (2019). Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nat Med 25, 95\u2013102.","journal-title":"Nat Med"},{"key":"3061_CR128","doi-asserted-by":"publisher","first-page":"109253","DOI":"10.1016\/j.intimp.2022.109253","volume":"112","author":"T Liu","year":"2022","unstructured":"Liu, T., Long, X., Zhang, Y., Jin, J., Chen, L., and Liu, A. (2022a). IP-10 enhances the amplification capacity and antitumor activity of CAR-T cells in vitro and could influence positive outcomes in MM patients treated with CAR-T cell therapy. Int Immunopharmacol 112, 109253.","journal-title":"Int Immunopharmacol"},{"key":"3061_CR129","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cr.2016.142","volume":"27","author":"X Liu","year":"2017","unstructured":"Liu, X., Zhang, Y., Cheng, C., Cheng, A.W., Zhang, X., Li, N., Xia, C., Wei, X., Liu, X., and Wang, H. (2017). CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res 27, 154\u2013157.","journal-title":"Cell Res"},{"key":"3061_CR130","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu, Y., An, L., Huang, R., Xiong, J., Yang, H., Wang, X., and Zhang, X. (2022b). Strategies to enhance CAR-T persistence. Biomark Res 10, 86.","journal-title":"Biomark Res"},{"key":"3061_CR131","doi-asserted-by":"publisher","first-page":"eabb5191","DOI":"10.1126\/scitranslmed.abb5191","volume":"13","author":"Y Liu","year":"2021","unstructured":"Liu, Y., Liu, G., Wang, J., Zheng, Z., Jia, L., Rui, W., Huang, D., Zhou, Z., Zhou, L., Wu, X., et al. (2021a). Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med 13, eabb5191.","journal-title":"Sci Transl Med"},{"key":"3061_CR132","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41590-020-00850-9","volume":"22","author":"Y Liu","year":"2021","unstructured":"Liu, Y., Zhou, N., Zhou, L., Wang, J., Zhou, Y., Zhang, T., Fang, Y., Deng, J., Gao, Y., Liang, X., et al. (2021b). IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor. Nat Immunol 22, 358\u2013369.","journal-title":"Nat Immunol"},{"key":"3061_CR133","doi-asserted-by":"publisher","first-page":"e006287","DOI":"10.1136\/jitc-2022-006287","volume":"11","author":"E Lopez","year":"2023","unstructured":"Lopez, E., Karattil, R., Nannini, F., Weng-Kit Cheung, G., Denzler, L., Galvez-Cancino, F., Quezada, S., and Pule, M.A. (2023). Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies. J Immunother Cancer 11, e006287.","journal-title":"J Immunother Cancer"},{"key":"3061_CR134","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/2159-8290.CD-22-1350","volume":"14","author":"S L\u00f3pez-Cobo","year":"2024","unstructured":"L\u00f3pez-Cobo, S., Fuentealba, J.R., Gueguen, P., Bont\u00e9, P.E., Tsalkitzi, K., Chac\u00f3n, I., Glauzy, S., Bohineust, A., Biquand, A., Silva, L., et al. (2024). SUV39H1 ablation enhances long-term CAR T function in solid tumors. Cancer Discov 14, 120\u2013141.","journal-title":"Cancer Discov"},{"key":"3061_CR135","doi-asserted-by":"publisher","first-page":"216660","DOI":"10.1016\/j.canlet.2024.216660","volume":"585","author":"Q Lu","year":"2024","unstructured":"Lu, Q., Yang, D., Li, H., Zhu, Z., Zhang, Z., Chen, Y., Yang, N., Li, J., Wang, Z., Niu, T., et al. (2024). Delivery of CD47-SIRP\u03b1 checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma. Cancer Lett 585, 216660.","journal-title":"Cancer Lett"},{"key":"3061_CR136","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-20-0777","volume":"26","author":"H Luo","year":"2020","unstructured":"Luo, H., Su, J., Sun, R., Sun, Y., Wang, Y., Dong, Y., Shi, B., Jiang, H., and Li, Z. (2020). Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion. Clin Cancer Res 26, 5494\u20135505.","journal-title":"Clin Cancer Res"},{"key":"3061_CR137","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.omto.2022.12.003","volume":"28","author":"J Lv","year":"2023","unstructured":"Lv, J., Qin, L., Zhao, R., Wu, D., Wu, Z., Zheng, D., Li, S., Luo, M., Wu, Q., Long, Y., et al. (2023). Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels. Mol Ther Oncolytics 28, 46\u201358.","journal-title":"Mol Ther Oncolytics"},{"key":"3061_CR138","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R.C., Weber, E.W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019). c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300.","journal-title":"Nature"},{"key":"3061_CR139","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0092-8674(02)00767-5","volume":"109","author":"F Maci\u00e1n","year":"2002","unstructured":"Maci\u00e1n, F., Garc\u00eda-C\u00f3zar, F., Im, S.H., Horton, H.F., Byrne, M.C., and Rao, A. (2002). Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109, 719\u2013731.","journal-title":"Cell"},{"key":"3061_CR140","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/0008-5472.CAN-16-1831","volume":"77","author":"S Mardiana","year":"2017","unstructured":"Mardiana, S., John, L.B., Henderson, M.A., Slaney, C.Y., von Scheidt, B., Giuffrida, L., Davenport, A.J., Trapani, J.A., Neeson, P.J., Loi, S., et al. (2017). A multifunctional role for adjuvant anti-4-1BB therapy in augmenting antitumor response by chimeric antigen receptor T cells. Cancer Res 77, 1296\u20131309.","journal-title":"Cancer Res"},{"key":"3061_CR141","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.trecan.2022.04.001","volume":"8","author":"F M\u00e4rkl","year":"2022","unstructured":"M\u00e4rkl, F., Huynh, D., Endres, S., and Kobold, S. (2022). Utilizing chemokines in cancer immunotherapy. Trends Cancer 8, 670\u2013682.","journal-title":"Trends Cancer"},{"key":"3061_CR142","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s40425-019-0719-5","volume":"7","author":"B Mastelic-Gavillet","year":"2019","unstructured":"Mastelic-Gavillet, B., Navarro Rodrigo, B., D\u00e9combaz, L., Wang, H., Ercolano, G., Ahmed, R., Lozano, L.E., Ianaro, A., Derr\u00e9, L., Valerio, M., et al. (2019). Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells. J Immunother Cancer 7, 257.","journal-title":"J Immunother Cancer"},{"key":"3061_CR143","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei, H., Li, C., Jiang, H., Zhao, X., Huang, Z., Jin, D., Guo, T., Kou, H., Liu, L., Tang, L., et al. (2021). A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol 14, 161.","journal-title":"J Hematol Oncol"},{"key":"3061_CR144","doi-asserted-by":"publisher","first-page":"1159337","DOI":"10.3389\/fimmu.2023.1159337","volume":"14","author":"AD Meringa","year":"2023","unstructured":"Meringa, A.D., Hern\u00e1ndez-L\u00f3pez, P., Cleven, A., de Witte, M., Straetemans, T., Kuball, J., Beringer, D.X., and Sebestyen, Z. (2023). Strategies to improve \u03b3\u03b4TCRs engineered T-cell therapies for the treatment of solid malignancies. Front Immunol 14, 1159337.","journal-title":"Front Immunol"},{"key":"3061_CR145","doi-asserted-by":"publisher","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","volume":"11","author":"K Mestermann","year":"2019","unstructured":"Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., and Hudecek, M. (2019). The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Transl Med 11, eaau5907.","journal-title":"Sci Transl Med"},{"key":"3061_CR146","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","volume":"39","author":"F Mo","year":"2021","unstructured":"Mo, F., Watanabe, N., McKenna, M.K., Hicks, M.J., Srinivasan, M., Gomes-Silva, D., Atilla, E., Smith, T., Ataca Atilla, P., Ma, R., et al. (2021a). Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol 39, 56\u201363.","journal-title":"Nat Biotechnol"},{"key":"3061_CR147","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41586-021-03861-0","volume":"597","author":"F Mo","year":"2021","unstructured":"Mo, F., Yu, Z., Li, P., Oh, J., Spolski, R., Zhao, L., Glassman, C.R., Yamamoto, T.N., Chen, Y., Golebiowski, F.M., et al. (2021b). An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature 597, 544\u2013548.","journal-title":"Nature"},{"key":"3061_CR148","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1002\/eji.202048934","volume":"51","author":"YR Mohseni","year":"2021","unstructured":"Mohseni, Y.R., Saleem, A., Tung, S.L., Dudreuilh, C., Lang, C., Peng, Q., Volpe, A., Adigbli, G., Cross, A., Hester, J., et al. (2021). Chimeric antigen receptor-modified human regulatory T cells that constitutively express IL-10 maintain their phenotype and are potently suppressive. Eur J Immunol 51, 2522\u20132530.","journal-title":"Eur J Immunol"},{"key":"3061_CR149","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/cells9040998","volume":"9","author":"T Nakazawa","year":"2020","unstructured":"Nakazawa, T., Natsume, A., Nishimura, F., Morimoto, T., Matsuda, R., Nakamura, M., Yamada, S., Nakagawa, I., Motoyama, Y., Park, Y.S., et al. (2020). Effect of CRISPR\/Cas9-mediated PD-1-disrupted primary human third-generation CAR-T cells targeting EGFRvIII on in vitro human glioblastoma cell growth. Cells 9, 998.","journal-title":"Cells"},{"key":"3061_CR150","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","volume":"11","author":"W Nawaz","year":"2021","unstructured":"Nawaz, W., Huang, B., Xu, S., Li, Y., Zhu, L., Yiqiao, H., Wu, Z., and Wu, X. (2021). AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J 11, 119.","journal-title":"Blood Cancer J"},{"key":"3061_CR151","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.3390\/cells11121974","volume":"11","author":"DT Nguyen","year":"2022","unstructured":"Nguyen, D.T., Ogando-Rivas, E., Liu, R., Wang, T., Rubin, J., Jin, L., Tao, H., Sawyer, W.W., Mendez-Gomez, H.R., Cascio, M., et al. (2022). CAR T cell locomotion in solid tumor microenvironment. Cells 11, 1974.","journal-title":"Cells"},{"key":"3061_CR152","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.iotech.2019.06.002","volume":"1","author":"O Nussbaumer","year":"2019","unstructured":"Nussbaumer, O., and Koslowski, M. (2019). The emerging role of \u03b3\u03b4 T cells in cancer immunotherapy. Immuno-Oncol Tech 1, 3\u201310.","journal-title":"Immuno-Oncol Tech"},{"key":"3061_CR153","doi-asserted-by":"publisher","first-page":"e1115940","DOI":"10.1080\/2162402X.2015.1115940","volume":"5","author":"P Ot\u00e1hal","year":"2016","unstructured":"Ot\u00e1hal, P., Pr\u016fkov\u00e1, D., Kr\u00e1l, V., Fabry, M., Vo\u010dkov\u00e1, P., Late\u010dkov\u00e1, L., Trn\u011bn\u00fd, M., and Klener, P. (2016). Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology 5, e1115940.","journal-title":"Oncoimmunology"},{"key":"3061_CR154","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.aah6499","volume":"359","author":"L Pace","year":"2018","unstructured":"Pace, L., Goudot, C., Zueva, E., Gueguen, P., Burgdorf, N., Waterfall, J.J., Quivy, J.P., Almouzni, G., and Amigorena, S. (2018). The epigenetic control of stemness in CD8+ T cell fate commitment. Science 359, 177\u2013186.","journal-title":"Science"},{"key":"3061_CR155","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1084\/jem.20150304","volume":"212","author":"DC Palmer","year":"2015","unstructured":"Palmer, D.C., Guittard, G.C., Franco, Z., Crompton, J.G., Eil, R.L., Patel, S.J., Ji, Y., Van Panhuys, N., Klebanoff, C.A., Sukumar, M., et al. (2015). Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med 212, 2095\u20132113.","journal-title":"J Exp Med"},{"key":"3061_CR156","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","volume":"14","author":"N Pang","year":"2021","unstructured":"Pang, N., Shi, J., Qin, L., Chen, A., Tang, Y., Yang, H., Huang, Y., Wu, Q., Li, X., He, B., et al. (2021). IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol 14, 118.","journal-title":"J Hematol Oncol"},{"key":"3061_CR157","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J.H., Rivi\u00e8re, I., Gonen, M., Wang, X., S\u00e9n\u00e9chal, B., Curran, K.J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018). Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378, 449\u2013459.","journal-title":"N Engl J Med"},{"key":"3061_CR158","doi-asserted-by":"publisher","first-page":"e92865","DOI":"10.1172\/jci.insight.92865","volume":"2","author":"A Pierini","year":"2017","unstructured":"Pierini, A., Iliopoulou, B.P., Peiris, H., P\u00e9rez-Cruz, M., Baker, J., Hsu, K., Gu, X., Zheng, P.P., Erkers, T., Tang, S.W., et al. (2017). T cells expressing chimeric antigen receptor promote immune tolerance. JCI Insight 2, e92865.","journal-title":"JCI Insight"},{"key":"3061_CR159","first-page":"1055","volume":"20","author":"R Pourakbari","year":"2021","unstructured":"Pourakbari, R., Hajizadeh, F., Parhizkar, F., Aghebati-Maleki, A., Mansouri, S., and Aghebati-Maleki, L. (2021). Co-stimulatory agonists: an insight into the immunotherapy of cancer. Excli J 20, 1055\u20131085.","journal-title":"Excli J"},{"key":"3061_CR160","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.molimm.2010.02.022","volume":"47","author":"N Pouw","year":"2010","unstructured":"Pouw, N., Treffers-Westerlaken, E., Mondino, A., Lamers, C., and Debets, R. (2010). TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity. Mol Immunol 47, 1411\u20131420.","journal-title":"Mol Immunol"},{"key":"3061_CR161","doi-asserted-by":"publisher","first-page":"h272","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing, B., Zebley, C.C., Petersen, C.T., Fan, Y., Anido, A.A., Yi, Z., Nguyen, P., Houke, H., Bell, M., Haydar, D., et al. (2021). Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci Transl Med 13, h272.","journal-title":"Sci Transl Med"},{"key":"3061_CR162","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper, D.J., and Balkwill, F.R. (2022). Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol 19, 237\u2013253.","journal-title":"Nat Rev Clin Oncol"},{"key":"3061_CR163","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","volume":"11","author":"H Qin","year":"2018","unstructured":"Qin, H., Ramakrishna, S., Nguyen, S., Fountaine, T.J., Ponduri, A., Stetler-Stevenson, M., Yuan, C.M., Haso, W., Shern, J.F., Shah, N.N., et al. (2018). Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol Ther Oncolytics 11, 127\u2013137.","journal-title":"Mol Ther Oncolytics"},{"key":"3061_CR164","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-017-0437-8","volume":"10","author":"L Qin","year":"2017","unstructured":"Qin, L., Lai, Y., Zhao, R., Wei, X., Weng, J., Lai, P., Li, B., Lin, S., Wang, S., Wu, Q., et al. (2017). Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. J Hematol Oncol 10, 68.","journal-title":"J Hematol Oncol"},{"key":"3061_CR165","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","volume":"34","author":"S Qiu","year":"2024","unstructured":"Qiu, S., Chen, J., Wu, T., Li, L., Wang, G., Wu, H., Song, X., Liu, X., and Wang, H. (2024). CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization. Cell Res 34, 386\u2013388.","journal-title":"Cell Res"},{"key":"3061_CR166","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fimmu.2020.00577","volume":"11","author":"Q Qu","year":"2020","unstructured":"Qu, Q., Zhu, X., Du, W., Wang, H., Shen, Y., Zhu, Y., and Chen, C. (2020). 4-1BB agonism combined with PD-L1 blockade increases the number of tissue-resident CD8+ T cells and facilitates tumor abrogation. Front Immunol 11, 577.","journal-title":"Front Immunol"},{"key":"3061_CR167","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/ni.2363","volume":"13","author":"FJ Quintana","year":"2012","unstructured":"Quintana, F.J., Jin, H., Burns, E.J., Nadeau, M., Yeste, A., Kumar, D., Rangachari, M., Zhu, C., Xiao, S., Seavitt, J., et al. (2012). Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat Immunol 13, 770\u2013777.","journal-title":"Nat Immunol"},{"key":"3061_CR168","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C.S., and Brentjens, R.J. (2020). Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17, 147\u2013167.","journal-title":"Nat Rev Clin Oncol"},{"key":"3061_CR169","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq, S., Yeku, O.O., Jackson, H.J., Purdon, T.J., van Leeuwen, D.G., Drakes, D.J., Song, M., Miele, M.M., Li, Z., Wang, P., et al. (2018). Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36, 847\u2013856.","journal-title":"Nat Biotechnol"},{"key":"3061_CR170","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41587-024-02339-4","volume":"43","author":"T Rakhshandehroo","year":"2025","unstructured":"Rakhshandehroo, T., Mantri, S.R., Moravej, H., Louis, B.B.V., Salehi Farid, A., Munaretto, L., Regan, K., Khan, R.M.M., Wolff, A., Farkash, Z., et al. (2025). A CAR enhancer increases the activity and persistence of CAR T cells. Nat Biotechnol 43, 948\u2013959.","journal-title":"Nat Biotechnol"},{"key":"3061_CR171","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","volume":"25","author":"S Ramakrishna","year":"2019","unstructured":"Ramakrishna, S., Highfill, S.L., Walsh, Z., Nguyen, S.M., Lei, H., Shern, J.F., Qin, H., Kraft, I.L., Stetler-Stevenson, M., Yuan, C.M., et al. (2019). Modulation of target antigen density improves CAR T-cell functionality and persistence. Clin Cancer Res 25, 5329\u20135341.","journal-title":"Clin Cancer Res"},{"key":"3061_CR172","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren, J., Liu, X., Fang, C., Jiang, S., June, C.H., and Zhao, Y. (2017a). Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 23, 2255\u20132266.","journal-title":"Clin Cancer Res"},{"key":"3061_CR173","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.18632\/oncotarget.15218","volume":"8","author":"J Ren","year":"2017","unstructured":"Ren, J., Zhang, X., Liu, X., Fang, C., Jiang, S., June, C.H., and Zhao, Y. (2017b). A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget 8, 17002\u201317011.","journal-title":"Oncotarget"},{"key":"3061_CR174","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","volume":"12","author":"A Rodriguez-Garcia","year":"2021","unstructured":"Rodriguez-Garcia, A., Lynn, R.C., Poussin, M., Eiva, M.A., Shaw, L.C., O\u2019Connor, R.S., Minutolo, N.G., Casado-Medrano, V., Lopez, G., Matsuyama, T., et al. (2021). CART cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun 12, 877.","journal-title":"Nat Commun"},{"key":"3061_CR175","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","volume":"126","author":"M Ruella","year":"2016","unstructured":"Ruella, M., Barrett, D.M., Kenderian, S.S., Shestova, O., Hofmann, T.J., Perazzelli, J., Klichinsky, M., Aikawa, V., Nazimuddin, F., Kozlowski, M., et al. (2016). Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 126, 3814\u20133826.","journal-title":"J Clin Invest"},{"key":"3061_CR176","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41435-024-00262-x","volume":"25","author":"M Saitakis","year":"2024","unstructured":"Saitakis, M. (2024). Epigenetic reprogramming of CAR T cells for in vivo functional persistence against solid tumors. Genes Immun 25, 434\u2013436.","journal-title":"Genes Immun"},{"key":"3061_CR177","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","volume":"45","author":"NE Scharping","year":"2016","unstructured":"Scharping, N.E., Menk, A.V., Moreci, R.S., Whetstone, R.D., Dadey, R.E., Watkins, S. C., Ferris, R.L., and Delgoffe, G.M. (2016). The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45, 374\u2013388.","journal-title":"Immunity"},{"key":"3061_CR178","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"NE Scharping","year":"2021","unstructured":"Scharping, N.E., Rivadeneira, D.B., Menk, A.V., Vignali, P.D.A., Ford, B.R., Ritten-house, N.L., Peralta, R., Wang, Y., Wang, Y., DePeaux, K., et al. (2021). Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol 22, 205\u2013215.","journal-title":"Nat Immunol"},{"key":"3061_CR179","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","volume":"22","author":"H Seo","year":"2021","unstructured":"Seo, H., Gonz\u00e1lez-Avalos, E., Zhang, W., Ramchandani, P., Yang, C., Lio, C.W.J., Rao, A., and Hogan, P.G. (2021). BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol 22, 983\u2013995.","journal-title":"Nat Immunol"},{"key":"3061_CR180","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","volume":"103","author":"H Shalabi","year":"2018","unstructured":"Shalabi, H., Kraft, I.L., Wang, H.W., Yuan, C.M., Yates, B., Delbrook, C., Zimbelman, J. D., Giller, R., Stetler-Stevenson, M., Jaffe, E.S., et al. (2018). Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica 103, e215\u2013e218.","journal-title":"Haematologica"},{"key":"3061_CR181","doi-asserted-by":"publisher","first-page":"e2103508","DOI":"10.1002\/advs.202103508","volume":"9","author":"M Shao","year":"2022","unstructured":"Shao, M., Teng, X., Guo, X., Zhang, H., Huang, Y., Cui, J., Si, X., Ding, L., Wang, X., Li, X., et al. (2022). Inhibition of calcium signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via SOCE-calcineurin-NFAT and glycolysis pathways. Adv Sci 9, e2103508.","journal-title":"Adv Sci"},{"key":"3061_CR182","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B.A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S.K., Poon, C., Gant, K.L., et al. (2023). Immune checkpoint therapy\u2014current perspectives and future directions. Cell 186, 1652\u20131669.","journal-title":"Cell"},{"key":"3061_CR183","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe, A.H., and Pauken, K.E. (2018). The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18, 153\u2013167.","journal-title":"Nat Rev Immunol"},{"key":"3061_CR184","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ajh.26486","volume":"97","author":"X Shi","year":"2022","unstructured":"Shi, X., Yan, L., Shang, J., Kang, L., Yan, Z., Jin, S., Zhu, M., Chang, H., Gong, F., Zhou, J., et al. (2022). Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol 97, 537\u2013547.","journal-title":"Am J Hematol"},{"key":"3061_CR185","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ymthe.2024.05.006","volume":"32","author":"Y Shi","year":"2024","unstructured":"Shi, Y., Kotchetkov, I.S., Dobrin, A., Hanina, S.A., Rajasekhar, V.K., Healey, J.H., and Sadelain, M. (2024). GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy. Mol Ther 32, 2393\u20132405.","journal-title":"Mol Ther"},{"key":"3061_CR186","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.immuni.2013.08.032","volume":"39","author":"HM Shin","year":"2013","unstructured":"Shin, H.M., Kapoor, V.N., Guan, T., Kaech, S.M., Welsh, R.M., and Berg, L.J. (2013). Epigenetic modifications induced by Blimp-1 regulate CD8+ T cell memory progression during acute virus infection. Immunity 39, 661\u2013675.","journal-title":"Immunity"},{"key":"3061_CR187","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","volume":"38","author":"J Si","year":"2020","unstructured":"Si, J., Shi, X., Sun, S., Zou, B., Li, Y., An, D., Lin, X., Gao, Y., Long, F., Pang, B., et al. (2020). Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies. Cancer Cell 38, 551\u2013566.e11.","journal-title":"Cancer Cell"},{"key":"3061_CR188","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cmet.2023.12.010","volume":"36","author":"X Si","year":"2024","unstructured":"Si, X., Shao, M., Teng, X., Huang, Y., Meng, Y., Wu, L., Wei, J., Liu, L., Gu, T., Song, J., et al. (2024). Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation. Cell Metab 36, 176\u2013192.e10.","journal-title":"Cell Metab"},{"key":"3061_CR189","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo, E., Barrett, D.M., Black, K.L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M.R., et al. (2015). Convergence of acquired mutations and alternative splicing of CD19 Enables resistance to CART-19 immunotherapy. Cancer Discov 5, 1282\u20131295.","journal-title":"Cancer Discov"},{"key":"3061_CR190","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin, D., Ghatwai, N., Montalbano, A., Rathi, P., Courtney, A.N., Arnett, A.B., Fleurence, J., Sweidan, R., Wang, T., Zhang, H., et al. (2025). Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637, 940\u2013946.","journal-title":"Nature"},{"key":"3061_CR191","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood.2020005185","volume":"136","author":"D Stenger","year":"2020","unstructured":"Stenger, D., Stief, T.A., Kaeuferle, T., Willier, S., Rataj, F., Schober, K., Vick, B., Lotfi, R., Wagner, B., Gr\u00fcnewald, T.G.P., et al. (2020). Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR. Blood 136, 1407\u20131418.","journal-title":"Blood"},{"key":"3061_CR192","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R.C., and Sterner, R.M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11, 69.","journal-title":"Blood Cancer J"},{"key":"3061_CR193","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cmet.2015.11.002","volume":"23","author":"M Sukumar","year":"2016","unstructured":"Sukumar, M., Liu, J., Mehta, G.U., Patel, S.J., Roychoudhuri, R., Crompton, J.G., Klebanoff, C.A., Ji, Y., Li, P., Yu, Z., et al. (2016). Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy. Cell Metab 23, 63\u201376.","journal-title":"Cell Metab"},{"key":"3061_CR194","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","volume":"31","author":"R Sun","year":"2023","unstructured":"Sun, R., Sun, Y., Wu, C., Liu, Y., Zhou, M., Dong, Y., Du, G., Luo, H., Shi, B., Jiang, H., et al. (2023). CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer. Mol Ther 31, 3193\u20133209.","journal-title":"Mol Ther"},{"key":"3061_CR195","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1158\/1078-0432.CCR-23-3298","volume":"30","author":"LJ Talbot","year":"2024","unstructured":"Talbot, L.J., Chabot, A., Ross, A.B., Beckett, A., Nguyen, P., Fleming, A., Chockley, P. J., Shepphard, H., Wang, J., Gottschalk, S., et al. (2024). Redirecting B7-H3.CAR T cells to chemokines expressed in osteosarcoma enhances homing and antitumor activity in preclinical models. Clin Cancer Res 30, 4434\u20134449.","journal-title":"Clin Cancer Res"},{"key":"3061_CR196","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-022-01244-0","volume":"15","author":"J Tan","year":"2022","unstructured":"Tan, J., Jia, Y., Zhou, M., Fu, C., Tuhin, I.J., Ye, J., Monty, M.A., Xu, N., Kang, L., Li, M., et al. (2022). Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells. J Hematol Oncol 15, 39.","journal-title":"J Hematol Oncol"},{"key":"3061_CR197","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang, L., Pan, S., Wei, X., Xu, X., and Wei, Q. (2023). Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development. Mol Ther 31, 3146\u20133162.","journal-title":"Mol Ther"},{"key":"3061_CR198","doi-asserted-by":"publisher","first-page":"e133977","DOI":"10.1172\/jci.insight.133977","volume":"5","author":"N Tang","year":"2020","unstructured":"Tang, N., Cheng, C., Zhang, X., Qiao, M., Li, N., Mu, W., Wei, X.F., Han, W., and Wang, H. (2020). TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight 5, e133977.","journal-title":"JCI Insight"},{"key":"3061_CR199","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40364-022-00359-3","volume":"10","author":"TCY Tang","year":"2022","unstructured":"Tang, T.C.Y., Xu, N., Nordon, R., Haber, M., Micklethwaite, K., and Dolnikov, A. (2022). Donor T cells for CAR T cell therapy. Biomark Res 10, 14.","journal-title":"Biomark Res"},{"key":"3061_CR200","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.2021.39.15_suppl.2527","volume":"39","author":"MT Tees","year":"2021","unstructured":"Tees, M.T., Neelapu, S.S., Hari, P., Mailankody, S., Miklos, D.B., Locke, F.L., Nath, R., Prashad, S.L., Zhou, X., Demirhan, E., et al. (2021). Safety and PK\/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)\/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy. J Clin Oncol 39, 2527.","journal-title":"J Clin Oncol"},{"key":"3061_CR201","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/mc.23202","volume":"59","author":"K Toews","year":"2020","unstructured":"Toews, K., Grunewald, L., Schwiebert, S., Klaus, A., Winkler, A., Ali, S., Zirngibl, F., Astrahantseff, K., Wagner, D.L., Henssen, A.G., et al. (2020). Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells. Mol Carcinog 59, 724\u2013735.","journal-title":"Mol Carcinog"},{"key":"3061_CR202","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/blood-2020-140907","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong, C., Zhang, Y., Liu, Y., Ji, X., Zhang, W., Guo, Y., Han, X., Ti, D., Dai, H., Wang, C., et al. (2020). Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B cell lymphoma. Blood 136, 1632\u20131644.","journal-title":"Blood"},{"key":"3061_CR203","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley, A.M., Rotiroti, M.C., Labanieh, L., Rysavy, L.W., Kim, W.J., Lareau, C., Sotillo, E., Weber, E.W., Rietberg, S.P., Dalton, G.N., et al. (2023). Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615, 507\u2013516.","journal-title":"Nature"},{"key":"3061_CR204","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.humimm.2011.12.020","volume":"73","author":"I Traverso","year":"2012","unstructured":"Traverso, I., Fenoglio, D., Negrini, S., Parodi, A., Battaglia, F., Kalli, F., Conteduca, G., Tardito, S., Traverso, P., Indiveri, F., et al. (2012). Cyclophosphamide inhibits the generation and function of CD8+ regulatory T cells. Hum Immunol 73, 207\u2013213.","journal-title":"Hum Immunol"},{"key":"3061_CR205","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41467-022-35583-w","volume":"14","author":"MP Trefny","year":"2023","unstructured":"Trefny, M.P., Kirchhammer, N., Auf der Maur, P., Natoli, M., Schmid, D., Germann, M., Fernandez Rodriguez, L., Herzig, P., L\u00f6tscher, J., Akrami, M., et al. (2023). Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy. Nat Commun 14, 86.","journal-title":"Nat Commun"},{"key":"3061_CR206","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/mt.2015.104","volume":"23","author":"J Valton","year":"2015","unstructured":"Valton, J., Guyot, V., Marechal, A., Filhol, J.M., Juillerat, A., Duclert, A., Duchateau, P., and Poirot, L. (2015). A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy. Mol Ther 23, 1507\u20131518.","journal-title":"Mol Ther"},{"key":"3061_CR207","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","volume":"36","author":"GJW van der Windt","year":"2012","unstructured":"van der Windt, G.J.W., Everts, B., Chang, C.H., Curtis, J.D., Freitas, T.C., Amiel, E., Pearce, E.J., and Pearce, E.L. (2012). Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36, 68\u201378.","journal-title":"Immunity"},{"key":"3061_CR208","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","volume":"5","author":"B Wang","year":"2021","unstructured":"Wang, B., Iriguchi, S., Waseda, M., Ueda, N., Ueda, T., Xu, H., Minagawa, A., Ishikawa, A., Yano, H., Ishi, T., et al. (2021a). Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat Biomed Eng 5, 429\u2013440.","journal-title":"Nat Biomed Eng"},{"key":"3061_CR209","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1158\/2159-8290.CD-20-1243","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang, D., Prager, B.C., Gimple, R.C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2021b). CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies. Cancer Discov 11, 1192\u20131211.","journal-title":"Cancer Discov"},{"key":"3061_CR210","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11427-023-2554-y","volume":"68","author":"J Wang","year":"2025","unstructured":"Wang, J., Zhou, W., Xu, Y., Duan, J., Zhou, Q., Wang, G., Li, L., Xu, C., Wang, W., Cai, S., et al. (2025). Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR\/OAK and CHOICE-01 trials. Sci China Life Sci 68, 249\u2013262.","journal-title":"Sci China Life Sci"},{"key":"3061_CR211","doi-asserted-by":"publisher","first-page":"e009476","DOI":"10.1136\/jitc-2024-009476","volume":"12","author":"T Wang","year":"2024","unstructured":"Wang, T., Yang, Y., Ma, L., Feng, R., Li, J., Zhang, C., Bai, J., Ding, Y., Liu, G., Wu, F., et al. (2024). BCMA-BBZ-OX40 CAR-T therapy using an instant manufacturing platform in multiple myeloma. J Immunother Cancer 12, e009476.","journal-title":"J Immunother Cancer"},{"key":"3061_CR212","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","volume":"24","author":"X Wang","year":"2018","unstructured":"Wang, X., Walter, M., Urak, R., Weng, L., Huynh, C., Lim, L., Wong, C.L.W., Chang, W.C., Thomas, S.H., Sanchez, J.F., et al. (2018). Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clin Cancer Res 24, 106\u2013119.","journal-title":"Clin Cancer Res"},{"key":"3061_CR213","doi-asserted-by":"publisher","first-page":"628906","DOI":"10.3389\/fimmu.2021.628906","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Wang, J., Yang, X., Yang, J., Lu, P., Zhao, L., Li, B., Pan, H., Jiang, Z., Shen, X., et al. (2021c). Chemokine receptor CCR2b enhanced anti-tumor function of chimeric antigen receptor T cells targeting mesothelin in a non-small-cell lung carcinoma model. Front Immunol 12, 628906.","journal-title":"Front Immunol"},{"key":"3061_CR214","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/cac2.12474","volume":"43","author":"Z Wang","year":"2023","unstructured":"Wang, Z., Lu, Y., Liu, Y., Mou, J., Liu, X., Chen, M., Wang, Y., Xu, Y., Rao, Q., Xing, H., et al. (2023). Novel CD123\u00d7CD33 bicistronic chimeric antigen receptor (CAR)-T therapy has potential to reduce escape from single-target CAR-T with no more hematotoxicity. Cancer Commun 43, 1178\u20131182.","journal-title":"Cancer Commun"},{"key":"3061_CR215","doi-asserted-by":"publisher","first-page":"096368972092082","DOI":"10.1177\/0963689720920825","volume":"29","author":"Z Wang","year":"2020","unstructured":"Wang, Z., Zhou, G., Risu, N., Fu, J., Zou, Y., Tang, J., Li, L., Liu, H., Liu, Q., and Zhu, X. (2020). Lenalidomide enhances CAR-T cell activity against solid tumor cells. Cell Transplant 29, 096368972092082.","journal-title":"Cell Transplant"},{"key":"3061_CR216","doi-asserted-by":"publisher","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber, E.W., Parker, K.R., Sotillo, E., Lynn, R.C., Anbunathan, H., Lattin, J., Good, Z., Belk, J.A., Daniel, B., Klysz, D., et al. (2021). Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786.","journal-title":"Science"},{"key":"3061_CR217","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei, S.C., Levine, J.H., Cogdill, A.P., Zhao, Y., Anang, N.A.A.S., Andrews, M.C., Sharma, P., Wang, J., Wargo, J.A., Pe\u2019er, D., et al. (2017). Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120\u20131133.e17.","journal-title":"Cell"},{"key":"3061_CR218","doi-asserted-by":"publisher","first-page":"7551","DOI":"10.1073\/pnas.1506357112","volume":"112","author":"B Weigelin","year":"2015","unstructured":"Weigelin, B., Bola\u00f1os, E., Teijeira, A., Martinez-Forero, I., Labiano, S., Azpilikueta, A., Morales-Kastresana, A., Quetglas, J.I., Wagena, E., S\u00e1nchez-Paulete, A.R., et al. (2015). Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proc Natl Acad Sci USA 112, 7551\u20137556.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3061_CR219","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-21-0694","volume":"12","author":"F Wiede","year":"2022","unstructured":"Wiede, F., Lu, K.H., Du, X., Zeissig, M.N., Xu, R., Goh, P.K., Xirouchaki, C.E., Hogarth, S.J., Greatorex, S., Sek, K., et al. (2022). PTP1B is an intracellular checkpoint that limits T-cell and CAR T-cell antitumor immunity. Cancer Discov 12, 752\u2013773.","journal-title":"Cancer Discov"},{"key":"3061_CR220","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","volume":"180","author":"S Wilkie","year":"2008","unstructured":"Wilkie, S., Picco, G., Foster, J., Davies, D.M., Julien, S., Cooper, L., Arif, S., Mather, S.J., Taylor-Papadimitriou, J., Burchell, J.M., et al. (2008). Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 180, 4901\u20134909.","journal-title":"J Immunol"},{"key":"3061_CR221","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson, W.R., and Hay, M.P. (2011). Targeting hypoxia in cancer therapy. Nat Rev Cancer 11, 393\u2013410.","journal-title":"Nat Rev Cancer"},{"key":"3061_CR222","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","volume":"18","author":"M Works","year":"2019","unstructured":"Works, M., Soni, N., Hauskins, C., Sierra, C., Baturevych, A., Jones, J.C., Curtis, W., Carlson, P., Johnstone, T.G., Kugler, D., et al. (2019). Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide. Mol Cancer Ther 18, 2246\u20132257.","journal-title":"Mol Cancer Ther"},{"key":"3061_CR223","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3390\/vaccines13060654","volume":"13","author":"Y Xian","year":"2025","unstructured":"Xian, Y., and Wen, L. (2025). CAR beyond \u03b1\u03b2 T cells: unleashing NK cells, macrophages, and \u03b3\u03b4 T lymphocytes against solid tumors. Vaccines 13, 654.","journal-title":"Vaccines"},{"key":"3061_CR224","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.3390\/cancers14133230","volume":"14","author":"B Xie","year":"2022","unstructured":"Xie, B., Li, Z., Zhou, J., and Wang, W. (2022). Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies. Cancers 14, 3230.","journal-title":"Cancers"},{"key":"3061_CR225","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1158\/2326-6066.CIR-19-0734","volume":"8","author":"YJ Xie","year":"2020","unstructured":"Xie, Y.J., Dougan, M., Ingram, J.R., Pishesha, N., Fang, T., Momin, N., and Ploegh, H. L. (2020). Improved antitumor efficacy of chimeric antigen receptor T cells that secrete single-domain antibody fragments. Cancer Immunol Res 8, 518\u2013529.","journal-title":"Cancer Immunol Res"},{"key":"3061_CR226","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1016\/j.apsb.2024.04.022","volume":"14","author":"D Xiong","year":"2024","unstructured":"Xiong, D., Yu, H., and Sun, Z.J. (2024). Unlocking T cell exhaustion: insights and implications for CAR-T cell therapy. Acta Pharm Sin B 14, 3416\u20133431.","journal-title":"Acta Pharm Sin B"},{"key":"3061_CR227","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ymthe.2018.01.020","volume":"26","author":"W Xiong","year":"2018","unstructured":"Xiong, W., Chen, Y., Kang, X., Chen, Z., Zheng, P., Hsu, Y.H., Jang, J.H., Qin, L., Liu, H., Dotti, G., et al. (2018). Immunological synapse predicts effectiveness of chimeric antigen receptor cells. Mol Ther 26, 963\u2013975.","journal-title":"Mol Ther"},{"key":"3061_CR228","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1016\/j.immuni.2024.11.005","volume":"57","author":"X Xu","year":"2024","unstructured":"Xu, X., Chen, H., Ren, Z., Xu, X., Wu, W., Yang, H., Wang, J.J., Zhang, Y., Zhou, Q., Li, H., et al. (2024). Phase separation of chimeric antigen receptor promotes immunological synapse maturation and persistent cytotoxicity. Immunity 57, 2755\u20132771.e8.","journal-title":"Immunity"},{"key":"3061_CR229","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y., Zhang, M., Ramos, C.A., Durett, A., Liu, E., Dakhova, O., Liu, H., Creighton, C. J., Gee, A.P., Heslop, H.E., et al. (2014). Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759.","journal-title":"Blood"},{"key":"3061_CR230","doi-asserted-by":"publisher","first-page":"e004400","DOI":"10.1136\/jitc-2021-004400","volume":"10","author":"Y Yamaguchi","year":"2022","unstructured":"Yamaguchi, Y., Gibson, J., Ou, K., Lopez, L.S., Ng, R.H., Leggett, N., Jonsson, V.D., Zarif, J.C., Lee, P.P., Wang, X., et al. (2022). PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages. J Immunother Cancer 10, e004400.","journal-title":"J Immunother Cancer"},{"key":"3061_CR231","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12967-024-05772-w","volume":"22","author":"Y Yan","year":"2024","unstructured":"Yan, Y., Tu, Y., Cheng, Q., Zhang, J., Wang, E., Deng, Z., Yu, Y., Wang, L., Liu, R., Chu, L., et al. (2024). BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed\/refractory multiple myeloma. J Transl Med 22, 1087.","journal-title":"J Transl Med"},{"key":"3061_CR232","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan, Z., Cao, J., Cheng, H., Qiao, J., Zhang, H., Wang, Y., Shi, M., Lan, J., Fei, X., Jin, L., et al. (2019). A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol 6, e521\u2013e529.","journal-title":"Lancet Haematol"},{"key":"3061_CR233","doi-asserted-by":"publisher","first-page":"20637","DOI":"10.1038\/s41598-021-00227-4","volume":"11","author":"X Yang","year":"2021","unstructured":"Yang, X., Yu, Q., Xu, H., and Zhou, J. (2021). Upregulation of CD22 by chidamide promotes CAR T cells functionality. Sci Rep 11, 20637.","journal-title":"Sci Rep"},{"key":"3061_CR234","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cmet.2022.02.009","volume":"34","author":"L Ye","year":"2022","unstructured":"Ye, L., Park, J.J., Peng, L., Yang, Q., Chow, R.D., Dong, M.B., Lam, S.Z., Guo, J., Tang, E., Zhang, Y., et al. (2022). A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab 34, 595\u2013614.e14.","journal-title":"Cell Metab"},{"key":"3061_CR235","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku, O.O., Purdon, T.J., Koneru, M., Spriggs, D., and Brentjens, R.J. (2017). Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep 7, 10541.","journal-title":"Sci Rep"},{"key":"3061_CR236","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.omto.2019.08.002","volume":"15","author":"Z Ying","year":"2019","unstructured":"Ying, Z., He, T., Wang, X., Zheng, W., Lin, N., Tu, M., Xie, Y., Ping, L., Zhang, C., Liu, W., et al. (2019). Parallel comparison of 4\u20131BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin\u2019s lymphoma. Mol Ther Oncolytics 15, 60\u201368.","journal-title":"Mol Ther Oncolytics"},{"key":"3061_CR237","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","volume":"129","author":"J Yoon","year":"2017","unstructured":"Yoon, J., Schmidt, A., Zhang, A.H., K\u00f6nigs, C., Kim, Y.C., and Scott, D.W. (2017). FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. Blood 129, 238\u2013245.","journal-title":"Blood"},{"key":"3061_CR238","doi-asserted-by":"publisher","first-page":"101526","DOI":"10.1016\/j.xcrm.2024.101526","volume":"5","author":"T Yoshikawa","year":"2024","unstructured":"Yoshikawa, T., Ito, Y., Wu, Z., Kasuya, H., Nakashima, T., Okamoto, S., Amaishi, Y., Zhang, H., Li, Y., Matsukawa, T., et al. (2024). Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. Cell Rep Med 5, 101526.","journal-title":"Cell Rep Med"},{"key":"3061_CR239","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1182\/blood.2021012714","volume":"139","author":"T Yoshikawa","year":"2022","unstructured":"Yoshikawa, T., Wu, Z., Inoue, S., Kasuya, H., Matsushita, H., Takahashi, Y., Kuroda, H., Hosoda, W., Suzuki, S., and Kagoya, Y. (2022). Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy. Blood 139, 2156\u20132172.","journal-title":"Blood"},{"key":"3061_CR240","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3389\/fimmu.2020.01787","volume":"11","author":"L You","year":"2020","unstructured":"You, L., Han, Q., Zhu, L., Zhu, Y., Bao, C., Yang, C., Lei, W., and Qian, W. (2020). Decitabine-mediated epigenetic reprograming enhances anti-leukemia efficacy of CD123-targeted chimeric antigen receptor T-cells. Front Immunol 11, 1787.","journal-title":"Front Immunol"},{"key":"3061_CR241","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","volume":"4","author":"E Zah","year":"2016","unstructured":"Zah, E., Lin, M.Y., Silva-Benedict, A., Jensen, M.C., and Chen, Y.Y. (2016). T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res 4, 498\u2013508.","journal-title":"Cancer Immunol Res"},{"key":"3061_CR242","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41375-020-01056-6","volume":"35","author":"C Zhang","year":"2021","unstructured":"Zhang, C., Wang, X.Q., Zhang, R.L., Liu, F., Wang, Y., Yan, Z.L., Song, Y.P., Yang, T., Li, P., Wang, Z., et al. (2021a). Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia 35, 1563\u20131570.","journal-title":"Leukemia"},{"key":"3061_CR243","doi-asserted-by":"publisher","first-page":"eaba7308","DOI":"10.1126\/scitranslmed.aba7308","volume":"13","author":"H Zhang","year":"2021","unstructured":"Zhang, H., Li, F., Cao, J., Wang, X., Cheng, H., Qi, K., Wang, G., Xu, K., Zheng, J., Fu, Y.X., et al. (2021b). A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. Sci Transl Med 13, eaba7308.","journal-title":"Sci Transl Med"},{"key":"3061_CR244","doi-asserted-by":"publisher","first-page":"811364","DOI":"10.3389\/fimmu.2021.811364","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang, J., Zhu, J., Zheng, G., Wang, Q., Li, X., Feng, Y., Shang, F., He, S., Jiang, Q., Shi, B., et al. (2021c). Co-expression of miR155 or LSD1 shRNA increases the antitumor functions of CD19 CAR-T cells. Front Immunol 12, 811364.","journal-title":"Front Immunol"},{"key":"3061_CR245","doi-asserted-by":"publisher","first-page":"1424719","DOI":"10.3389\/fnins.2024.1424719","volume":"18","author":"L Zhang","year":"2024","unstructured":"Zhang, L., Chen, S., Zou, R., Shu, X., Zhang, J., He, X., Su, M., Wang, L., Wang, B., and Sha, D. (2024). Cocaine amphetamine-regulated transcription peptide inhibits apoptosis in oxygen-glucose deprived neural stem cells. Front Neurosci 18, 1424719.","journal-title":"Front Neurosci"},{"key":"3061_CR246","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2217\/imt-2018-0012","volume":"10","author":"P Zhang","year":"2018","unstructured":"Zhang, P., Zhao, S., Wu, C., Li, J., Li, Z., Wen, C., Hu, S., An, G., Meng, H., Zhang, X., et al. (2018). Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages. Immunotherapy 10, 935\u2013949.","journal-title":"Immunotherapy"},{"key":"3061_CR247","doi-asserted-by":"publisher","first-page":"g6986","DOI":"10.1126\/scitranslmed.abg6986","volume":"13","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q., Hresko, M.E., Picton, L.K., Su, L., Hollander, M.J., Nunez-Cruz, S., Zhang, Z., Assenmacher, C.A., Sockolosky, J.T., Garcia, K.C., et al. (2021d). A human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Sci Transl Med 13, g6986.","journal-title":"Sci Transl Med"},{"key":"3061_CR248","first-page":"788","volume":"43","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q., and Xiao, Y. (2022). Relapse mechanism and coping strategies of CD19 chimeric antigen receptor T cells in the treatment of diffuse large B-cell lymphoma (in Chinese). Chin J Hematol, 43, 788\u2013792.","journal-title":"Chin J Hematol"},{"key":"3061_CR249","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","volume":"40","author":"X Zhang","year":"2022","unstructured":"Zhang, X., Zhang, C., Qiao, M., Cheng, C., Tang, N., Lu, S., Sun, W., Xu, B., Cao, Y., Wei, X., et al. (2022). Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell 40, 1407\u20131422.e7.","journal-title":"Cancer Cell"},{"key":"3061_CR250","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","volume":"11","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y., Zhang, X., Cheng, C., Mu, W., Liu, X., Li, N., Wei, X., Liu, X., Xia, C., and Wang, H. (2017). CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Front Med 11, 554\u2013562.","journal-title":"Front Med"},{"key":"3061_CR251","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/procel\/pwae034","volume":"16","author":"L Zhao","year":"2025","unstructured":"Zhao, L., Li, S., Wei, X., Qi, X., Guo, Q., Shi, L., Zhang, J.S., Li, J., Liu, Z.L., Guo, Z., et al. (2025a). A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies. Protein Cell 16, 227\u2013231.","journal-title":"Protein Cell"},{"key":"3061_CR252","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y., Chen, J., Andreatta, M., Feng, B., Xie, Y.Q., Wenes, M., Wang, Y., Gao, M., Hu, X., Romero, P., et al. (2024). IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol 42, 1693\u20131704.","journal-title":"Nat Biotechnol"},{"key":"3061_CR253","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/cancers17060998","volume":"17","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y., Li, Y., Wang, S., Han, J., Lu, M., Xu, Y., Qiao, W., Cai, M., Xu, Y., Hu, Y., et al. (2025b). CAR-\u03b3\u03b4 T cells targeting claudin18.2 show superior cytotoxicity against solid tumor compared to traditional CAR-\u03b1\u03b2 T cells. Cancers 17, 998.","journal-title":"Cancers"},{"key":"3061_CR254","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z., Condomines, M., van der Stegen, S.J.C., Perna, F., Kloss, C.C., Gunset, G., Plotkin, J., and Sadelain, M. (2015). Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428.","journal-title":"Cancer Cell"},{"key":"3061_CR255","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s11427-023-2556-4","volume":"68","author":"C Zheng","year":"2025","unstructured":"Zheng, C., Song, L., Yu, C., Zhu, L., Zhang, J., Wang, N., Liu, M., Li, S., Wang, L., Shen, Z., et al. (2025a). Palindrome-mediated DNA nanotubes with cell-specific aptamers to improve targeted antitumor effects and reduce toxicity on non-small cell lung cancer. Sci China Life Sci 68, 454\u2013466.","journal-title":"Sci China Life Sci"},{"key":"3061_CR256","doi-asserted-by":"crossref","unstructured":"Zheng, R., Zhang, J., Zhou, J., Zhang, Z., Niu, M., Fei, J., Wu, K., Yi, M., and Li, T. (2025b). Development and application of antibody-drug conjugates in gynecological cancers. Sci China Life Sci 68.","DOI":"10.1007\/s11427-025-3016-4"},{"key":"3061_CR257","doi-asserted-by":"publisher","first-page":"8893","DOI":"10.2147\/CMAR.S260915","volume":"12","author":"JT Zhou","year":"2020","unstructured":"Zhou, J.T., Liu, J.H., Song, T.T., Ma, B., Amidula, N., and Bai, C. (2020). EGLIF-CAR-T cells secreting PD-1 blocking antibodies significantly mediate the elimination of gastric cancer. Cancer Manag Res Volume 12, 8893\u20138902.","journal-title":"Cancer Manag Res Volume"},{"key":"3061_CR258","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41590-023-01571-5","volume":"24","author":"X Zhou","year":"2023","unstructured":"Zhou, X., Cao, H., Fang, S.Y., Chow, R.D., Tang, K., Majety, M., Bai, M., Dong, M.B., Renauer, P.A., Shang, X., et al. (2023). CTLA-4 tail fusion enhances CAR-T antitumor immunity. Nat Immunol 24, 1499\u20131510.","journal-title":"Nat Immunol"},{"key":"3061_CR259","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12032-022-01913-7","volume":"40","author":"X Zhu","year":"2023","unstructured":"Zhu, X., Li, W., Gao, J., Shen, J., Xu, Y., Zhang, C., and Qian, C. (2023). RUNX3 improves CAR-T cell phenotype and reduces cytokine release while maintaining CAR-T function. Med Oncol 40, 89.","journal-title":"Med Oncol"},{"key":"3061_CR260","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41590-023-01685-w","volume":"25","author":"Z Zhu","year":"2024","unstructured":"Zhu, Z., Lou, G., Teng, X.L., Wang, H., Luo, Y., Shi, W., Yihunie, K., Hao, S., DeGolier, K., Liao, C., et al. (2024). FOXP1 and KLF2 reciprocally regulate checkpoints of stem-like to effector transition in CAR T cells. Nat Immunol 25, 117\u2013128.","journal-title":"Nat Immunol"},{"key":"3061_CR261","doi-asserted-by":"publisher","first-page":"101422","DOI":"10.1016\/j.xcrm.2024.101422","volume":"5","author":"JT Zoine","year":"2024","unstructured":"Zoine, J.T., Immadisetty, K., Ibanez-Vega, J., Moore, S.E., Nevitt, C., Thanekar, U., Tian, L., Karouni, A., Chockley, P.J., Arthur, B., et al. (2024). Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity. Cell Rep Med 5, 101422.","journal-title":"Cell Rep Med"},{"key":"3061_CR262","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jcyt.2018.07.005","volume":"20","author":"SN Zolov","year":"2018","unstructured":"Zolov, S.N., Rietberg, S.P., and Bonifant, C.L. (2018). Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells. Cytotherapy 20, 1259\u20131266.","journal-title":"Cytotherapy"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3061-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-025-3061-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3061-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:03:13Z","timestamp":1775545393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-025-3061-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":262,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3061"],"URL":"https:\/\/doi.org\/10.1007\/s11427-025-3061-8","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}